Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Prognostic Significance of Interactions Between ER Alpha and ER Beta and Lymph Node Status in Breast Cancer Cases

  • Han, Shu-Jing (Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University) ;
  • Guo, Qing-Qing (Beijing Friend Hospital, Capital University of Medical Sciences) ;
  • Wang, Ting (Departments of General Surgery, Xinjing Hospital, Xi'an) ;
  • Wang, You-Xin (Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University) ;
  • Zhang, Yu-Xiang (Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University) ;
  • Liu, Fen (Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University) ;
  • Luo, Yan-Xia (Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University) ;
  • Zhang, Jie (Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University) ;
  • Wang, You-Li (Peking University People's Hospital) ;
  • Yan, Yu-Xiang (Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University) ;
  • Peng, Xiao-Xia (Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University) ;
  • Ling, Rui (Departments of General Surgery, Xinjing Hospital, Xi'an) ;
  • He, Yan (Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University)
  • Published : 2013.10.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: Both estrogen receptors, ER alpha ($ER{\alpha}$) and ER beta ($ER{\beta}$), are expressed in 50-70% of breast cancer cases. The role of $ER{\alpha}$ as a prognostic marker in breast cancer has been well established as its expression is negative correlated with tumor size and lymph node metastasis. $ER{\beta}$ is also a favorable prognostic predictor although this is less well documented than for $ER{\alpha}$. Materials and Methods: To explore whether ERs independently or together might influence clinical outcome in breast cancer, the correlation between the ERs with the clinicopathological features was analyzed in 84 patients. Results: $ER{\alpha}$ expression negatively correlated with tumor stage (r=-0.246, p=0.028) and tended to be negatively correlated with lymph node status (r=-0.156, p=0.168) and tumor size (r=-0.246, p=0.099). Also, $ER{\beta}$ was negatively correlated with nodal status (r=-0.243, p=0.028), as was coexpression of $ER{\alpha}$ and $ER{\beta}$ (p=0.043, OR=0.194, 95% CI= 0.040-0.953). Conclusion: Coexpression of ERs might serve as an indicator of good prognosis in breast cancer patients.

Keywords

References

  1. Fleming FJ, Hill AD, McDermott EW, O'Higgins NJ, Young LS (2004). Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer. J Clin Endocrinol Metab, 89, 375-83. https://doi.org/10.1210/jc.2003-031048
  2. Fuqua SA, Schiff R, Parra I, et al (2003). Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res, 63, 2434-9
  3. Jarvinen TA, Pelto-Huikko M, Holli K, Isola J (2000). Estrogen receptor beta is coexpressed with ER alpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol, 156, 29-35. https://doi.org/10.1016/S0002-9440(10)64702-5
  4. Jordan VC, Brodie AM (2007).Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids, 72, 7-25. https://doi.org/10.1016/j.steroids.2006.10.009
  5. Kirschner MA (1977). The role of hormones in the etiology of human breast cancer. Cancer, 39, 2716-26. https://doi.org/10.1002/1097-0142(197706)39:6<2716::AID-CNCR2820390659>3.0.CO;2-3
  6. Koda M, Sulkowski S, Kanczuga-Koda L, Surmacz E, Sulkowska M (2004). Expression of ER alpha, ER beta and Ki-67 in primary tumors and lymph node metastases in breast cancer. Oncol Rep, 11, 753-9.
  7. Lacey JV, Jr., Devesa SS, Brinton LA (2002). Recent trends in breast cancer incidence and mortality. Environ Mol Mutagen, 39, 82-8. https://doi.org/10.1002/em.10062
  8. Lin CY, Strom A, Li Kong S, et al (2007). Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer. Breast Cancer Res, 9, R25. https://doi.org/10.1186/bcr1667
  9. McGuire WL (1978). Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol, 5, 428-33.
  10. Murphy L, Cherlet T, Lewis A, Banu Y, Watson P (2003). New insights into estrogen receptor function in human breast cancer. Ann Med, 35, 614-31. https://doi.org/10.1080/07853890310014579
  11. Nilsson S, Makela S, Treuter E, et al (2001). Mechanisms of estrogen action. Physiol Rev, 81, 1535-65.
  12. Omoto Y, Kobayashi S, Inoue S, et al (2002). Evaluation of oestrogen receptor beta wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. Eur J Cancer, 38, 380-6. https://doi.org/10.1016/S0959-8049(01)00383-5
  13. O'Neill PA, Davies MP, Shaaban AM, et al (2004). Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers. Br J Cancer, 91, 1694-702.
  14. Osborne CK (1998). Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat, 51, 227-38. https://doi.org/10.1023/A:1006132427948
  15. Page DL, Fleming ID, Fritz A (2002). AJCC Cancer Staging Manual 6th edition. breast cancer. Lippincott-Raven, Philadelphia, Pa, USA.
  16. Pettersson K, Delaunay F, Gustafsson JA (2000). Estrogen receptor beta acts as a dominant regulator of estrogen signaling. Oncogene, 19, 4970-8. https://doi.org/10.1038/sj.onc.1203828
  17. Platet N, Cathiard AM, Gleizes M, Garcia M (2004). Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol, 51, 55-67 . https://doi.org/10.1016/j.critrevonc.2004.02.001
  18. Reisenbichler ES, Lester SC, Richardson AL, et al (2013). Interobserver Concordance in Implementing the 2010 ASCO/CAP Recommendations for Reporting ER in Breast Carcinomas: A Demonstration of the Difficulties of Consistently Reporting Low Levels of ER Expression by Manual Quantification. Am J Clin Pathol, 140, 487-94 https://doi.org/10.1309/AJCP1RF9FUIZRDPI
  19. Robertson JF (1996). Oestrogen receptor: a stable phenotype in breast cancer. Br J Cancer, 73, 5-12. https://doi.org/10.1038/bjc.1996.2
  20. Rochefort H, Platet N, Hayashido Y, et al (1998).Estrogen receptor mediated inhibition of cancer cell invasion and motility: an overview. J Steroid Biochem Mol Biol, 65, 163-8. https://doi.org/10.1016/S0960-0760(98)00010-7
  21. Sofi GN, Sofi JN, Nadeem R (2012). Estrogen receptor and progesterone receptor status in breast cancer in relation to age, histological grade, size of lesion and lymph node involvement. Asian Pac J Cancer Prev, 13, 5047-52 . https://doi.org/10.7314/APJCP.2012.13.10.5047
  22. Speirs V, Parkes AT, Kerin MJ, et al (1999).Coexpression of estrogen receptor alpha and beta: poor prognostic factors in human breast cancer? Cancer Res, 59, 525-8.
  23. Sugiura H, Toyama T, Hara Y, et al (2007).Expression of estrogen receptor beta wild-type and its variant ERbetacx/beta2 is correlated with better prognosis in breast cancer. Jpn J Clin Oncol, 37, 820-8 . https://doi.org/10.1093/jjco/hym114
  24. Umemura S, Kurosumi M, Moriya T, et al (2006). Immunohistochemical evaluation for hormone receptors in breast cancer: a practically useful evaluation system and handling protocol. Breast Cancer, 13, 232-5. https://doi.org/10.2325/jbcs.13.232
  25. Williams C, Edvardsson K, Lewandowski SA, Strom A, Gustafsson JA (2008). A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells. Oncogene, 27, 1019-32. https://doi.org/10.1038/sj.onc.1210712
  26. Williams G, Anderson E, Howell A, et al (1991) .Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast. Int J Cancer, 48, 206-10. https://doi.org/10.1002/ijc.2910480209
  27. Younes M, Honma N (2011): Estrogen receptor beta. Arch Pathol Lab Med, 135, 63-6.
  28. Ziegler RG, Anderson WF, Gail MH (2008).Increasing breast cancer incidence in China: the numbers add up. J Natl Cancer Inst, 100, 1339-41. https://doi.org/10.1093/jnci/djn330

Cited by

  1. Benefit of Post-mastectomy Radiotherapy of the Supra-/infraclavicular Lymphatic Drainage Area in Breast Cancer Patients vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5557
  2. Long-Term Survival of Women with Locally Advanced Breast Cancer with ≥10 Involved Lymph Nodes at Diagnosis vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3435
  3. Autocrine interferon-γ may affect malignant behavior and sensitivity to tamoxifen of MCF-7 via estrogen receptor β subtype vol.34, pp.6, 2015, https://doi.org/10.3892/or.2015.4294
  4. Awareness and current knowledge of breast cancer vol.50, pp.1, 2017, https://doi.org/10.1186/s40659-017-0140-9